Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

Rhea-AI Summary

Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in the upcoming Bank of America Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET. Investors and interested parties can access the live webcast through the Investors section of Acumen's website at www.acumenpharm.com, where the recording will remain available for 90 days.

News Market Reaction – ABOS

+0.37%

+0.37% Session move

In the trading session that priced this news, ABOS gained 0.37%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET.

The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.   

Investors:
Alex Braun
abraun@acumenpharm.com 

Media: 
AcumenPR@westwicke.com 

FAQ

When is Acumen Pharmaceuticals (ABOS) presenting at the Bank of America Healthcare Conference 2025?

Acumen Pharmaceuticals will present at the Bank of America Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET.

What is Acumen Pharmaceuticals (ABOS) developing for Alzheimer's disease?

Acumen Pharmaceuticals is developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease.

How can investors access Acumen Pharmaceuticals' (ABOS) presentation at the Bank of America Healthcare Conference?

Investors can access the live webcast through the Investors tab on www.acumenpharm.com. The recording will be archived for 90 days.

What stage of development is Acumen Pharmaceuticals (ABOS)?

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company.